SynthesisFrontiers in medicine2025
Advances and frontiers in pulmonary fibrosis and lung cancer research (2000-2024): a bibliometric analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in orofacial pain research: a bibliometric analysis.Frontiers in neurology · 2025Pooled it
- The Fibrotic-Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide. In pulmonary fibrosis (PF), the incidence of lung cancer is elevated, and its prognosis is worse compared to the general population. With the development of related research, the relationship between lung cancer and pulmonary fibrosis has received close attention. However, comprehensive and objective reports on this topic remain scarce. Therefore, this study aims to identify research hotspots and visualize evolving trends and collaboration networks in the field of pulmonary fibrosis and lung cancer using bibliometric and knowledge mapping tools. Methods: Articles in the field of pulmonary fibrosis and lung cancer were retrieved using the Web of Science core collection subject search, and bibliometric analysis was performed in CiteSpace, VOSviewer, ChiPlot (https://www.chiplot.online/) and Bibliometrix (R-Tool of R-Studio). Results: This bibliometric analysis included 1,830 publications from 2000 to 2024, showing a steady increase over time. Collaborative network analysis identifies Japan, the United States, and China as the most influential countries, contributing the highest publications and citations. Respiratory Research is the leading journal. Bade BC is a key author, with Lung Cancer 2020: Epidemiology, Etiology, and Prevention as the most cited work. Literature and keyword analyses indicate a primary focus on diagnosis and survival, with recent shifts toward gene regulation and pulmonary inflammation. Emerging research highlights epithelial-mesenchymal transition (EMT) and chronic inflammation in lung cancer development among IPF patients. Notably, studies on immune checkpoint inhibitors (e.g., PD-1/PD-L1) have surged, reflecting a growing interest in immunotherapy. Conclusion: This study is the first to employ bibliometric methods to visualize research trends and frontiers in pulmonary fibrosis and lung cancer. Our analysis reveals a shift from early studies on diagnosis and prognosis toward a growing focus on molecular mechanisms and immunotherapy. These findings offer valuable insights into emerging research directions and may serve as a reference for researchers seeking to identify key topics and potential collaborators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.